PortalPublikationenPlatelet activation parameters and platelet-leucocyte-conjug...

Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients

Standard

Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. / Marx, Sascha; Splittstöhser, Maximilian; Kinnen, Frederik; Moritz, Eileen; Joseph, Christy; Paul, Sebastian; Paland, Heiko; Seifert, Carolin; Marx, Madlen; Böhm, Andreas; Schwedhelm, Edzard; Holzer, Kerstin; Singer, Stephan; Ritter, Christoph A; Bien-Möller, Sandra; Schroeder, Henry W S; Rauch, Bernhard H.

in: ONCOTARGET, Jahrgang 9, Nr. 40, 25.05.2018, S. 25860-25876.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Marx, S, Splittstöhser, M, Kinnen, F, Moritz, E, Joseph, C, Paul, S, Paland, H, Seifert, C, Marx, M, Böhm, A, Schwedhelm, E, Holzer, K, Singer, S, Ritter, CA, Bien-Möller, S, Schroeder, HWS & Rauch, BH 2018, 'Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients', ONCOTARGET, Jg. 9, Nr. 40, S. 25860-25876. https://doi.org/10.18632/oncotarget.25395

APA

Marx, S., Splittstöhser, M., Kinnen, F., Moritz, E., Joseph, C., Paul, S., Paland, H., Seifert, C., Marx, M., Böhm, A., Schwedhelm, E., Holzer, K., Singer, S., Ritter, C. A., Bien-Möller, S., Schroeder, H. W. S., & Rauch, B. H. (2018). Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. ONCOTARGET, 9(40), 25860-25876. https://doi.org/10.18632/oncotarget.25395

Vancouver

Marx S, Splittstöhser M, Kinnen F, Moritz E, Joseph C, Paul S et al. Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. ONCOTARGET. 2018 Mai 25;9(40):25860-25876. https://doi.org/10.18632/oncotarget.25395

Bibtex

@article{b6d9c55068dc49d2bc4f664a72754438,
title = "Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients",
abstract = "Patients with glioblastoma multiforme (GBM) suffer from an increased incidence of vascular thrombotic events. However, key influencing factors of the primary hemostasis have not been characterized in GBM patients to date. Thus, the present study determines the activation level of circulating platelets in GBM patients, in-vitro reactivity to agonist-induced platelet stimulation and the formation of circulating platelet-leucocyte conjugates as well as the plasma levels of the proinflammatory lipid mediator sphingosine-1-phosphate (S1P). The endogenous thrombin potential (ETP) was determined as global marker for hemostasis. The 21 GBM patients and 21 gender and age matched healthy individuals enrolled in this study did not differ in mean total platelet count. Basal surface expression of platelet CD63 determined by flow cytometry was significantly increased in GBM patients compared to controls as was observed for the concentration of soluble P-selectin in the plasma of GBM patients. While the ETP was not affected, the immunomodulatory lipid S1P was significantly decreased in peripheral blood in GBM. Interestingly, monocyte expression of PSGL-1 (CD162) was decreased in GBM patient blood, possibly explaining the rather decreased formation of platelet-monocyte conjugates. Our study reveals an increased CD63 expression and P-selectin expression/ secretion of circulating platelets in GBM patients. In parallel a down-modulated PSGL-1 expression in circulating monocytes and a trend towards a decreased formation of heterotypic platelet-monocyte conjugates in GBM patients was seen. Whether this and the observed decreased plasma level of the immunomodulatory S1P reflects a systemic anti-inflammatory status needs to be addressed in future studies.",
keywords = "Journal Article",
author = "Sascha Marx and Maximilian Splittst{\"o}hser and Frederik Kinnen and Eileen Moritz and Christy Joseph and Sebastian Paul and Heiko Paland and Carolin Seifert and Madlen Marx and Andreas B{\"o}hm and Edzard Schwedhelm and Kerstin Holzer and Stephan Singer and Ritter, {Christoph A} and Sandra Bien-M{\"o}ller and Schroeder, {Henry W S} and Rauch, {Bernhard H}",
year = "2018",
month = may,
day = "25",
doi = "10.18632/oncotarget.25395",
language = "English",
volume = "9",
pages = "25860--25876",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "40",

}

RIS

TY - JOUR

T1 - Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients

AU - Marx, Sascha

AU - Splittstöhser, Maximilian

AU - Kinnen, Frederik

AU - Moritz, Eileen

AU - Joseph, Christy

AU - Paul, Sebastian

AU - Paland, Heiko

AU - Seifert, Carolin

AU - Marx, Madlen

AU - Böhm, Andreas

AU - Schwedhelm, Edzard

AU - Holzer, Kerstin

AU - Singer, Stephan

AU - Ritter, Christoph A

AU - Bien-Möller, Sandra

AU - Schroeder, Henry W S

AU - Rauch, Bernhard H

PY - 2018/5/25

Y1 - 2018/5/25

N2 - Patients with glioblastoma multiforme (GBM) suffer from an increased incidence of vascular thrombotic events. However, key influencing factors of the primary hemostasis have not been characterized in GBM patients to date. Thus, the present study determines the activation level of circulating platelets in GBM patients, in-vitro reactivity to agonist-induced platelet stimulation and the formation of circulating platelet-leucocyte conjugates as well as the plasma levels of the proinflammatory lipid mediator sphingosine-1-phosphate (S1P). The endogenous thrombin potential (ETP) was determined as global marker for hemostasis. The 21 GBM patients and 21 gender and age matched healthy individuals enrolled in this study did not differ in mean total platelet count. Basal surface expression of platelet CD63 determined by flow cytometry was significantly increased in GBM patients compared to controls as was observed for the concentration of soluble P-selectin in the plasma of GBM patients. While the ETP was not affected, the immunomodulatory lipid S1P was significantly decreased in peripheral blood in GBM. Interestingly, monocyte expression of PSGL-1 (CD162) was decreased in GBM patient blood, possibly explaining the rather decreased formation of platelet-monocyte conjugates. Our study reveals an increased CD63 expression and P-selectin expression/ secretion of circulating platelets in GBM patients. In parallel a down-modulated PSGL-1 expression in circulating monocytes and a trend towards a decreased formation of heterotypic platelet-monocyte conjugates in GBM patients was seen. Whether this and the observed decreased plasma level of the immunomodulatory S1P reflects a systemic anti-inflammatory status needs to be addressed in future studies.

AB - Patients with glioblastoma multiforme (GBM) suffer from an increased incidence of vascular thrombotic events. However, key influencing factors of the primary hemostasis have not been characterized in GBM patients to date. Thus, the present study determines the activation level of circulating platelets in GBM patients, in-vitro reactivity to agonist-induced platelet stimulation and the formation of circulating platelet-leucocyte conjugates as well as the plasma levels of the proinflammatory lipid mediator sphingosine-1-phosphate (S1P). The endogenous thrombin potential (ETP) was determined as global marker for hemostasis. The 21 GBM patients and 21 gender and age matched healthy individuals enrolled in this study did not differ in mean total platelet count. Basal surface expression of platelet CD63 determined by flow cytometry was significantly increased in GBM patients compared to controls as was observed for the concentration of soluble P-selectin in the plasma of GBM patients. While the ETP was not affected, the immunomodulatory lipid S1P was significantly decreased in peripheral blood in GBM. Interestingly, monocyte expression of PSGL-1 (CD162) was decreased in GBM patient blood, possibly explaining the rather decreased formation of platelet-monocyte conjugates. Our study reveals an increased CD63 expression and P-selectin expression/ secretion of circulating platelets in GBM patients. In parallel a down-modulated PSGL-1 expression in circulating monocytes and a trend towards a decreased formation of heterotypic platelet-monocyte conjugates in GBM patients was seen. Whether this and the observed decreased plasma level of the immunomodulatory S1P reflects a systemic anti-inflammatory status needs to be addressed in future studies.

KW - Journal Article

U2 - 10.18632/oncotarget.25395

DO - 10.18632/oncotarget.25395

M3 - SCORING: Journal article

C2 - 29899827

VL - 9

SP - 25860

EP - 25876

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 40

ER -